公开(公告)号：AU6205200A

公开(公告)日：2001-01-22

申请号：AU6205200

申请日：2000-06-30

Applicant: LIPTON STUART A

Inventor： LIPTON STUART A

IPC: C07D401/04 ,  A61K31/00 ,  A61K31/424 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/506 ,  A61K45/00 ,  A61P3/08 ,  A61P3/10 ,  A61P9/10 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P27/06 ,  A61P39/02 ,  A61P43/00 ,  C07D401/14 ,  C07D413/04 ,  C07D471/04 ,  C07D513/04 ,  A61K31/40 ,  A61K31/44 ,  A61K31/415

Abstract: The invention relates to a method of reducing neuronal injury or apoptosis including administering to a patient in need thereof an effective amount of a p38 mitogen-activated protein kinase (MAPK) inhibitor. Methods of treating an HIV-mediated dementia, glaucoma, or other neurodegenerative disorders are also disclosed.

公开(公告)号：WO2008108825A3

公开(公告)日：2008-12-18

申请号：PCT/US2007021748

申请日：2007-10-10

Applicant: BURNHAM INST MEDICAL RESEARCH ,  LIPTON STUART A ,  SATOH TAKUMI

Inventor： LIPTON STUART A ,  SATOH TAKUMI

IPC: A01N33/02 ,  A61K31/13

CPC classification number: C07C62/32 ,  C07C62/38 ,  C07C69/757 ,  C07C2602/26

Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keapl, a negative regulator of the transcription factor Nrf2, and prevent Keapl -mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keapl /Nrf2 complex.

Abstract translation: 神经突起伸展促进前列腺素（NEPPs）和其它电子化合物结合Keapl，转录因子Nrf2的负调节物，并防止Keapl介导的Nrf2的失活，因此，提高Nrf2的易位到神经元细胞的细胞核中。 因此，提供了神经保护组合物和相关方法，其使用这样的神经保护性化合物以及这些化合物的前体药物来引起Nrf2从Keap1 / Nrf2复合体解离。

公开(公告)号：WO2005019166A3

公开(公告)日：2006-09-14

申请号：PCT/US2004019045

申请日：2004-06-14

Applicant: NEUROMOLECULAR INC ,  WENT GREGORY T ,  WASLEY JAN W F ,  LIPTON STUART A ,  LARRICK JAMES W ,  MEYERSON LAURENCE R ,  STAMLER JONATHAN S

Inventor： WENT GREGORY T ,  WASLEY JAN W F ,  LIPTON STUART A ,  LARRICK JAMES W ,  MEYERSON LAURENCE R ,  STAMLER JONATHAN S

IPC: A61K31/445 ,  A61K31/13 ,  A61K31/40 ,  C07D20060101

CPC classification number: A61K31/40 ,  A61K47/51

Abstract: Disclosed are conjugates in which an aminoadamantane derivative, such as amantadine, memantine, or rimantadine is linked to a therapeutic agent. The conjugate can then be used to target the therapeutic agent to an injured neuron.

Abstract translation: 公开了其中氨基金刚烷衍生物如金刚烷胺，美金刚或金刚烷胺与治疗剂连接的缀合物。 然后可以将缀合物用于将治疗剂靶向损伤的神经元。

公开(公告)号：WO2011085213A3

公开(公告)日：2011-09-15

申请号：PCT/US2011020536

申请日：2011-01-07

Applicant: SANFORD BURNHAM MED RES INST ,  LIPTON STUART A

Inventor： LIPTON STUART A

IPC: G01N33/53

CPC classification number: G01N33/53

Abstract: Disclosed are methods and compositions for identifying, producing, and using pathologically-activated targeting compounds. Pathologically- activated compounds are compound that only have an effect, or have a disproportionate effect, on a target molecule when a pathological condition exists.

Abstract translation: 公开了用于鉴定，产生和使用病理活化的靶向化合​​物的方法和组合物。 当存在病理状况时，病理活化的化合物是仅对靶分子具有作用或具有不成比例的作用的化合物。

公开(公告)号：WO2005110468A2

公开(公告)日：2005-11-24

申请号：PCT/US2005016248

申请日：2005-05-10

Applicant: BURNHAM INST ,  LIPTON STUART A ,  EINHORN DANIEL

Inventor： LIPTON STUART A ,  EINHORN DANIEL

IPC: A61K38/22 ,  A61K38/31

CPC classification number: A61K38/31

Abstract: This invention relates to Applicant's discovery that Metabolic Syndrome, a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with beta-amyloid protein for the IDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.

Abstract translation: 本发明涉及申请人的发现，代谢综合征是由抗胰岛素引起的一系列疾病，直接导致痴呆，特别是阿尔茨海默氏病。 申请人的发明包括基于代谢综合征的危险因素确定痴呆的易感性和诊断的筛选方法。 申请人的发明还包括基于（1）使胰岛素抵抗最小化从而防止胰岛素过量生物合成来预防或治疗痴呆和其他神经病症的方法; （2）调节IDE的活性，使得胰岛素与IDE的β-淀粉样蛋白不太有效地竞争; 和（3）阻止NMDA受体活化的后果，例如通过最小化NO和其他有害自由基的产生。